To Investigate the Influence of Ethnicity in Metabolic Disease in Healthy, Overweight and Obese Subjects

Healthy Clinical Trial

— SAMS-1  

Official title:

Developmental Pathways to Metabolic Diseases: Metabolic Physiology, Epigenetics and Body Composition in Healthy Overweight and Obese Subjects With a Fixed Range of Body Mass Index in Singapore - To Investigate the Influence of Ethnicity

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00988819
• Other study ID #: DSRB C/09/022
• Status: Recruiting
• Phase: N/A
• First received: October 1, 2009
• Last updated: February 28, 2010
• Start date: July 2009

Study information

• Verified date: February 2010
• Source: National University Hospital, Singapore
• Contact: n/a
• Is FDA regulated: No
• Health authority: Singapore: Domain Specific Review Boards
• Study type: Observational

Clinical Trial Summary

The overall objective of this study is to investigate in depth the nature of metabolic physiology, body composition and epigenetic differences of the different phenotypes of overweight and obese individuals who are otherwise overtly healthy among the three major ethnic groups in Singapore.

Description:

Over the past decade, investigators in Singapore have been actively studying the impact of ethnicity on metabolic traits, particularly those related to insulin resistance (detailed in the preliminary data of this proposal. We have observed that, for the same BMI, Asian Indians appear to have greater insulin resistance than Chinese. In line with the greater insulin resistance observed in Asian Indians, it has also been noted that Asian Indians exhibit greater central obesity (manifest as a larger waist circumference). In some ways, this resembles the phenotype that might be expected if the mismatch pathway described in this proposal, were involved in the pathogenesis of insulin resistance in this ethnic group. Interestingly, Asian Indians have also been noted to have lower birth weight than Chinese in our population. In contrast, although Malays are more insulin resistant than Chinese, this is largely due to greater adiposity and, after adjustment for body mass index, Malays are actually less insulin resistant than their Chinese and Asian Indian counterparts. They also have smaller waist circumferences. It is also recognized that pregnant Malay women tend to be generally more obese than their Chinese and Asian Indian counterparts, which may put their children at great risk of fetal hyperinsulinemia. As such, the potential exists that this latter pathway is more active in the pathogenesis of insulin resistance in this ethnic group.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 21 Years to 40 Years

Eligibility

Inclusion Criteria:

1. Ability to give informed consent

2. Chinese, Malay or Indian males (aged 21-40)

3. Body mass index between 23-30 kg/m2 for the overweight or obese subjects and between 18.5 to 22.9 kg/m2 for the Chinese control group

4. Sedentary adults < 1 episode of exercise > =30 min/week

5. Birth weight between 3-97% percentiles

6. Fasting glucose < 7 mmol/L

7. Normotensive, defined as BP < 140/90 mmHg and not on any antihypertensive agents

Exclusion Criteria:

1. Recent changes in weight of > 5% over the past 6 months

2. Attempts to lose weight (weight not reaching equilibrium, exercises still changing and not in maintenance phase) over the past 6 months

3. Significant changes in diet over the past 6 months

4. Any use of weight reducing drugs in the past 6 months

5. Previous abdominal surgery (and bariatric surgery)

6. Any bleeding disorders which would preclude biopsies

7. Any use of investigational drugs in the past 6 months

8. Known allergy to insulin or local anesthetics

9. Known allergy to milk or milk products (eg. Ensure)

10. Any serious illness requiring hospitalization or surgery in the past 6 months

11. Treatment with medications for hypertension, diabetes mellitus or dyslipidemia, epilepsy, ischemic heart disease

12. On anti-platelet agents, non-steroidal anti-inflammatory drugs (NSAIDs) or anticoagulants

13. Use of any prescription medication that cannot be safely discontinued within 14 days prior to study entry

14. Any use of corticosteroids in the past 6 months

15. Any other medications that could alter insulin resistance

16. History of surgery with metallic clips, staples or stents

17. Presence of cardiac pacemaker or other foreign body in any part of the body

18. Mother no longer alive or unable to provide information on birth weight

19. Born premature (ie. not full term baby < 37 weeks of gestation age)

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Healthy
• Metabolic Diseases
• Obesity
• Overweight

Locations

Country	Name	City	State
Singapore	National University Hospital	Singapore

Sponsors (2)

Lead Sponsor	Collaborator
National University Hospital, Singapore	National Medical Research Council (NMRC), Singapore

Country where clinical trial is conducted

Singapore,